Companies: 10,795·Total market cap: $144.5T
Aktis Oncology, Inc.

Aktis Oncology, Inc.

AKTSNASDAQHealthcare● Active
$18.97
+$0.10(+0.53%)
Market Cap$1.0B
P/E Ratio—
52W High$29.16
52W Low$14.72
SEC Filings

Aktis Oncology, Inc. (AKTS) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0002035832 · AKTS · NASDAQ · as of Jun 9, 2026

Filing snapshot

50
Total Filings
SCHEDULE 13G
Latest Form
2026-05-14
Most Recent
2026
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0002035832 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-30
Fiscal Year End
Mar 30, 2026
Accession No.
0001193125-26-131748
Primary Document
aktis_12.31.25_10k.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0002035832 · Accession 0001193125-26-131748

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-11
View 10-Q on SEC
8-KCurrent Report
8-K
2026-05-11Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-14
View
10-QQuarterly Report
10-Q
2026-05-11
View
8-KCurrent Report
8-K
2026-05-11
View
3Initial Statement of Beneficial Ownership
3
2026-04-16
View
8-KCurrent Report
8-K
2026-04-16
View
8-KCurrent Report
8-K
2026-03-30
View
10-KAnnual Report
10-K
2026-03-30
View
SCHEDULE 13DSCHEDULE 13D
SCHEDULE 13D
2026-01-20
View
SCHEDULE 13DSCHEDULE 13D
SCHEDULE 13D
2026-01-20
View
SCHEDULE 13DSCHEDULE 13D
SCHEDULE 13D
2026-01-15
View
3Initial Statement of Beneficial Ownership
3
2026-01-15
View
SCHEDULE 13DSCHEDULE 13D
SCHEDULE 13D
2026-01-14
View
S-8Employee Stock Plan Registration
S-8
2026-01-12
View
8-KCurrent Report
8-K
2026-01-12
View
424B4424B4
424B4
2026-01-09
View
Showing 1–15 of 42 filingsForm 4 / 144 hidden· 50 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0002035832  |  Exchange: NASDAQ · Healthcare

Aktis Oncology, Inc. (NASDAQ: AKTS) has submitted 50 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2026. As a Healthcare sector company with CIK 0002035832, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Aktis Oncology, Inc.'s most comprehensive regulatory disclosure. The most recent Aktis Oncology, Inc. 10-K was filed on 2026-03-30 for fiscal year ending 2026. Historical AKTS 10-K annual reports are available from 2024 through 2026.

Investors researching Aktis Oncology, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
→ AKTS Financials→ AKTS Earnings→ AKTS Insider Trades

Frequently Asked Questions

AKTS SEC Filings · 8 questions

Aktis Oncology, Inc. (AKTS) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 50 filings and access original documents at no cost. Aktis Oncology, Inc.'s CIK is 0002035832.

AKTS SEC filingsAktis Oncology, Inc. SEC documentsfind AKTS 10-K